Clinical Trial Update: A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

View source ↗

Summary

A clinical study analyzing risk factors for liver injury linked to PD-1/PD-L1 inhibitors in lung cancer patients; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• PD-1/PD-L1 inhibitors (PD-1/PD-L1 inhibitors)

Snippet

Sponsor: Zhejiang University | Conditions: Immune Checkpoint Inhibitors, Liver Injury | Status: RECRUITING